Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2008-08-04
2010-10-05
Lucas, Zachariah (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S387300, C530S388100
Reexamination Certificate
active
07807796
ABSTRACT:
The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient. ULBP polypeptides stimulate IFN-γ production, NK cell proliferation, and CTL activity.
REFERENCES:
patent: 4959314 (1990-09-01), Mark et al.
patent: 5474771 (1995-12-01), Lederman et al.
patent: RE38824 (2005-10-01), Salahuddin et al.
patent: 6953842 (2005-10-01), Vandlen et al.
patent: 2002/0197674 (2002-12-01), Ashkenzai et al.
Ahn and Kunkel, “The structural and functional diversity of dystrophin,”Nat Genet3:283-291, 1993.
Bauer et al., “Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA,”Science 285:727-729, 1999.
Bork P., “Powers and pitfalls in sequence analysis: the 70% hurdle,”Genome Research10:398-400, 2000.
Bowie et al., “Deciphering the message in protein tolerance to amino acid substitutions,”Science 247:1306-1310, 1990.
Burgess et al., “Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (Acidic Fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue,”Journal of Cell Biology 111:2129-2138, 1990.
Cao et al., “UL16 binding protein,”ImmunobiologyCOI 209, pp. 283-290, 2004.
Cawthon, RM et al., “cDNA sequence and genomic structure ofEV12B, a gene lying within an intron of the neurofibromatosis type 1 gene,”Genomics 9:446-460, 1991.
Cerwenka et al., “Retinoic acid earlyinducible genes define a ligand family for the activating NKG2D receptor in mice,”Immunity12:721-727, 2000.
Colucci et al., “Functional dichotomy in natural killer cell signaling: Vav1-dependent and -independent mechanisms,”J. Exp. Med. 193(12):1413-1424, 2001.
Cruse et al., Illustrated dictionary of immunology, CRC Press Inc. Boca Raton, FL (1995) pp. 171-172.
Diefenbach, A, et al., “Rael and H60 ligands of the NKG2D receptor stimulate tumour immunity,”Nature413:165-171, 2001.
Dorfman, D. et al., “In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation,”Blood 90(11):4297-4306, 1997.
Gattei, V, et al., “CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin,”Blood 89(6):2048-2059, 1997.
GenBank Accession No. AI091180, 1997.
GenBank EST Database Accession No. AI830832, (gi:5451425) (see USPTO Search Report US-09-597-2.rst, result 1), Jul. 12, 1999.
GenBank Accession No. U56940 (gi:1708675), “Human MHC class I chain-related gene A (MICA 001 allele), partial cds,” Jan. 22, 1997.
GenBank Accession No. U65416 (gi:1815636), “Human MHC class I molecule (MICB) gene, complete cds,” Feb. 5, 1997.
GenBank Accession No. R25716, 1995.
Girardi, M, et al., “Regulation of cutaneous malignancy by γδ T cells,”Science294:605-609, 2001.
Gura, T, “Systems for identifying drugs are often faulty,”Science 278:1041-1042, 1997.
Harris, PC et al., “Polycystic kidney disease 1: identification and analysis of the primary defect,”J Am Soc Nephrol6:1125-1133, 1995.
Janeway et al., Immunobiology, Current Biology Ltd., London (1994) pp. 9:20-9:24.
Lazar et al., “Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities,”Molecular and Cellular Biology 8:1247-1252, 1998.
Luo et al., “Rat hepatic natural killer cells (pit cells) express mRNA and protein similar to in Vitro Interleukin-2 activated spleen natural killer cells,”Cell. Immunol. 210:41-48, 2001.
Myers, D and Uckun, F, “An anti-CD72 immunotoxin against therapy-refractory B-lineage acute lymphoblastic leukemia,”Leukemia and Lymphoma 18:119-122, Harwood Academic Publishers GmbH, Printed in Singapore, 1995.
Scott et al., “The pendered syndrome gene encodes a chloride-iodide transport protein,”Nature Genetics21:440-443, 1999.
Song et al., “Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression,”Cellular Immunology 239(1):22-30, 2006.
Steinle, A, et al., Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family,Immunogenetics53:279-287, 2001.
Sun, T, et al., “Histiocyte-rich B-cell lymphoma,”Human Pathology 28(11):1321-1324, 1997.
Sutherland et al., “UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells,”J Immunol168:671-679, 2002.
Whiteside, T and Herberman, R, “The role of natural killer cells in immune surveillance of cancer,”Current Opinion in Immunology 7:704-710, 1995.
Yamabe et al., “Induction of the 2B9 antigen/dipeptiy1 peptidase IV/CD26 on human natural killer cells by IL-2, IL-12 and IL-15,”Immunology91:151-158, 1997.
Zurawski, S. et al., “Definition and spatial location of mouse interleukin-2 residues that interact with its heterotrimeric receptor,”EMBO J. 12(13):5113-5119, 1993.
Armitage Richard J
Cosman David J
Fanslow, III William C
Kubin Marek Z
Mullberg Jurgen
Immunex Corporation
Lingenfelter Susan E.
Lucas Zachariah
LandOfFree
ULBP antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ULBP antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ULBP antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4227801